ANDA 205222, held by Lannett Co Inc. Levofloxacin.
As of Nov 16, 2026, ANDA 205222 (Levofloxacin), held by Lannett Co Inc, was first approved by FDA on May 25, 2018, with 1 approved supplement and 0 published complete response letters.
Levofloxacin oral solution is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1, 12.4 ). Pneumonia: Nosocomial and Community Acquired ( 1.2, 1.3 ) Skin and Skin Structure Infections: Complicated and Uncomplicated Chronic bacterial prostatitis Inhalational Anthrax, Post-Exposure Plague Urinary Tract Infections: Complicated ( 1.9, 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 25, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levofloxacin250MG/10ML · solution;oral | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 25, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters